FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
NEW YORK, Dec. 07, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Arrowhead Pharmaceuticals, Inc. (“Arrowhead”) (NASDAQ:ARWR) between May 11, 2015 and November 29, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Central District of California. To get more information go to:
http://www.zlk.com/pslra/arrowhead-pharmaceuticals
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the Class Period, Arrowhead made false and misleading statements and/or failed to disclose that: (1) its drug candidate ARC-520 was fatal at certain doses; (2) the U.S. Food & Drug Administration was unlikely to approve ARC-520 as a hepatitis B treatment; (3) the Company overstated the approval prospects and commercial viability of ARC-520; and (4) as a result of the above, Arrowhead’s public statements were materially false and misleading at all relevant times.
On November 8, 2016, after the close of the market, Arrowhead Pharmaceuticals announced that the United States Food & Drug Administration had decided to place a clinical hold on the Company’s Heparc-2004 clinical study of ARC-520. Then on November 29, 2016, Arrowhead announced it would discontinue the development of 3 hepatitis treatments and trim its workforce by 30 percent.
If you suffered a loss in Arrowhead you have until January 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
